Ameriprise’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.8M | Sell |
355,588
-4,616
| -1% | -$138K | ﹤0.01% | 1798 |
|
|
2025
Q4 | $10.7M | Sell |
360,204
-12,711
| -3% | -$415K | ﹤0.01% | 1860 |
|
|
2025
Q3 | $13.5M | Sell |
372,915
-23,149
| -6% | -$763K | ﹤0.01% | 1685 |
|
|
2025
Q2 | $14.3M | Sell |
396,064
-29,918
| -7% | -$1.11M | ﹤0.01% | 1565 |
|
|
2025
Q1 | $16.8M | Sell |
425,982
-33,055
| -7% | -$1.11M | ﹤0.01% | 1422 |
|
|
2024
Q4 | $13.8M | Sell |
459,037
-335
| -0.1% | -$9.61K | ﹤0.01% | 1578 |
|
|
2024
Q3 | $10.7M | Buy |
459,372
+327,029
| +247% | +$7.14M | ﹤0.01% | 1723 |
|
|
2024
Q2 | $2.35M | Buy |
132,343
+1,925
| +1% | +$30.7K | ﹤0.01% | 2796 |
|
|
2024
Q1 | $1.98M | Buy |
130,418
+3,600
| +3% | +$57.3K | ﹤0.01% | 2877 |
|
|
2023
Q4 | $2.16M | Buy |
126,818
+63,760
| +101% | +$741K | ﹤0.01% | 2832 |
|
|
2023
Q3 | $527K | Sell |
63,058
-8,705
| -12% | -$121K | ﹤0.01% | 3393 |
|
|
2023
Q2 | $1.78M | Sell |
71,763
-100
| -0.1% | -$2.58K | ﹤0.01% | 2930 |
|
|
2023
Q1 | $1.08M | Buy |
+71,863
| New | +$1.09M | ﹤0.01% | 3112 |
|
|
2021
Q3 | – | Sell |
-5,217
| Closed | -$203K | – | 3962 |
|
|
2021
Q2 | $203K | Buy |
+5,217
| New | +$205K | ﹤0.01% | 3746 |
|
|
2021
Q1 | – | Sell |
-3,951
| Closed | -$206K | – | 3900 |
|
|
2020
Q4 | $206K | Buy |
+3,951
| New | +$133K | ﹤0.01% | 3615 |
|
|
2020
Q2 | – | Sell |
-30,905
| Closed | -$304K | – | 3734 |
|
|
2020
Q1 | $304K | Buy |
30,905
+15,847
| +105% | +$200K | ﹤0.01% | 3298 |
|
|
2019
Q4 | $167K | Buy |
+15,058
| New | +$114K | ﹤0.01% | 3602 |
|
|
2018
Q1 | – | Sell |
-95,704
| Closed | -$785K | – | 3689 |
|
|
2017
Q4 | $785K | Sell |
95,704
-84,947
| -47% | -$742K | ﹤0.01% | 3066 |
|
|
2017
Q3 | $2.14M | Sell |
180,651
-96,584
| -35% | -$1.1M | ﹤0.01% | 2580 |
|
|
2017
Q2 | $2.79M | Buy |
277,235
+166,434
| +150% | +$1.86M | ﹤0.01% | 2438 |
|
|
2017
Q1 | $1.29M | Buy |
+110,801
| New | +$795K | ﹤0.01% | 2776 |
|
|
2015
Q3 | – | Sell |
-97,285
| Closed | -$1.61M | – | 3938 |
|
|
2015
Q2 | $1.61M | Buy |
97,285
+25,216
| +35% | +$399K | ﹤0.01% | 2877 |
|
|
2015
Q1 | $1.12M | Sell |
72,069
-27,395
| -28% | -$415K | ﹤0.01% | 2887 |
|
|
2014
Q4 | $1.58M | Buy |
99,464
+5,489
| +6% | +$71.5K | ﹤0.01% | 2661 |
|
|
2014
Q3 | $1M | Buy |
93,975
+93,955
| +469,775% | +$871K | ﹤0.01% | 2802 |
|
|
2014
Q2 | $0 | Buy |
+20
| New | +$128 | ﹤0.01% | 5654 |
|
|
2013
Q4 | – | Sell |
-967
| Closed | -$5K | – | 5407 |
|
|
2013
Q3 | $5K | Buy |
967
+171
| +21% | +$1.05K | ﹤0.01% | 5236 |
|
|
2013
Q2 | $5K | Buy |
+796
| New | +$5.1K | ﹤0.01% | 5143 |
|
Other funds holding TGTX
VPM
VCM
SCM
CAM
Ameriprise's TGTX Position: Q1 2026 in Review
Ameriprise reduced its TG Therapeutics (TGTX) stake by 1.3% in Q1 2026, selling an estimated $138K and leaving 355,588 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1798.
Ameriprise first reported a position in TGTX in Q2 2013 and has held it in 28 quarters since. The position peaked at $16.8M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.
- Ameriprise held 355,588 shares of TG Therapeutics worth $11.8M as of Q1 2026.
- Ameriprise sold 4,616 TG Therapeutics shares in Q1 2026, an estimated $138K.
- TG Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1798 holding.
- Ameriprise first reported a position in TG Therapeutics in Q2 2013 and has held it in 28 quarters since.
- Ameriprise's TG Therapeutics position peaked at $16.8M in Q1 2025.
- 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.